Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial
Published in:
Transfuze Hematol. dnes,21, 2015, No. 1, p. 46.
Category:
Selection of press reports and books
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2015 Issue 1
- Neutralizing Antibodies Against Emicizumab – Detailed Analysis Based on a Case Study
- Position of aPCC in the Treatment of Hemophilia A Complicated by the Development of Inhibitors
- Sport and Physical Activity Benefit Hemophiliacs
- What FVIII Levels Are Ideal for Preventing Bleeding in Hemophilia A?
- Administration of aPCC as a Prevention of Bleeding After Major Cardiac Surgical Procedures
Most read in this issue
- Infectious complications of induction therapy in acute myeloid leukaemia patients without the use of antibiotic prophylaxis
- Interference of blood plasma components in turbidimetric D-dimer estimation
- Invasive fungal infections following autologous hematopoietic stem cell transplantation in patients with multiple myeloma
- Engraftment of acute and chronic myeloid leukemia in NOD scid gamma mice